LFG
AVBP icon

Larson Financial Group’s ArriVent BioPharma AVBP Stock Holding History

Larson Financial Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.39K Sell
277
-191
-41% -$4.31K ﹤0.01% 2481
2025
Q4 		$9.42K Buy
468
+454
+3,243% +$9.45K ﹤0.01% 2147
2025
Q3 		$258 Buy
+14
New +$275 ﹤0.01% 3223

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Larson Financial Group's AVBP Position: Q1 2026 in Review

Larson Financial Group reduced its ArriVent BioPharma (AVBP) stake by 41% in Q1 2026, selling an estimated $4.31K and leaving 277 shares worth $6.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Larson Financial Group first reported a position in AVBP in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.42K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Larson Financial Group held 277 shares of ArriVent BioPharma worth $6.39K as of Q1 2026.
  • Larson Financial Group sold 191 ArriVent BioPharma shares in Q1 2026, an estimated $4.31K.
  • ArriVent BioPharma made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2481 holding.
  • Larson Financial Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 3 quarters since.
  • Larson Financial Group's ArriVent BioPharma position peaked at $9.42K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.